We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Robert Fontana

Robert J. Fontana MD

Professor of Medicine; Medical Director of Liver Transplantation, University of Michigan, Ann Arbor, Michigan

Dr. Fontana is a translational investigator with research interests in drug induced liver injury, acute liver failure, and viral hepatitis. Dr. Fontana is currently a Professor of Medicine and Medical Director of Liver Transplantation.  He is a site investigator and co-chair of the Drug Induced Liver Injury Network (DILIN), an NIH consortium of sites investigating the pathogenesis and outcomes of DILI.  Dr. Fontana is also the current Chair of the AASLD Hepatotoxicity Special Interest Group and has been a leading member of the US Acute Liver Failure Study Group since 1998.  

Disclosures

Dr. Fontana receives research funding from the National Institutes of Health, Gilead Sciences, Bristol-MyersSquibb, Janssen pharmaceuticals, and Vertex.